Relevant clinical trials have demonstrated that AKT inhibitors such as capivasertib and ipatasertib play a significant role in the PI3K/AKT/mTOR signaling pathway, both occupying important positions in the treatment of metastatic triple-negative breast cancer (TNBC) (31, 32). This evidence concerns the gene MTOR and triple-negative breast carcinoma.